^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    GlycoVision™

    Company:
    Intervenn Biosci
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    4ms
    Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER (ESMO 2024)
    Our results indicate potential role for protein fucsosylation and sialylation mechanisms in driving resistance to NIVO+CABO and SUN in aRCC. Serum glycoproteins involved in complement cascade and lipid metabolism were predictive of response to NIVO+CABO vs SUN in aRCC.
    PD(L)-1 Biomarker • Metastases
    |
    AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding)
    |
    GlycoVision™
    |
    Opdivo (nivolumab) • sunitinib • Cabometyx (cabozantinib tablet)
    1year
    InterVenn Biosciences announces the publication of early detection of advanced adenoma and colorectal cancer in Gastroenterology, the flagship journal of the American Gastroenterological Association (Intervenn Biosciences Press Release)
    "InterVenn Biosciences...announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology. This groundbreaking research in early detection of CRC represents an advancement in early diagnosis through serum glycoproteome profiling. InterVenn’s GlycoVision™ platform leverages advanced liquid chromatography-mass spectrometry (LC-MS) combined with artificial intelligence (AI) and neural networks (NN) to interrogate a new layer of biology, enabling novel insights and discoveries."
    Clinical data
    |
    GlycoVision™
    over1year
    InterVenn demonstrates power of its GlycoVision™ platform in advanced adenoma and colorectal cancer (Intervenn Biosciences Press Release)
    "InterVenn Biosciences...presented new data at the 2023 Digestive Disease Week (DDW) annual conference, which was honored as a 'Poster of Distinction'. This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™, analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC). Separately, AA (N=32) was predicted with 87.5% sensitivity and CRC with 89.4% sensitivity. The sensitivity results of 87.5% for AA prediction is the highest that has been reported to date in the industry."
    Retrospective data
    |
    GlycoVision™
    over1year
    InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023 (Businesswire)
    "InterVenn Biosciences...announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™, to detect advanced adenomas (AA) and colorectal cancer (CRC). The data will be presented as a 'Poster of Distinction' at the 2023 Digestive Disease Week Conference (DDW), being held May 6-9, in Chicago, IL....The abstract...highlights pre-cancer sensitivity via the assessment of circulating serum glycoproteins and has been selected as a 'Poster of Distinction' by the American Gastroenterology Association (AGA) Institute Council, among the top 10 percent of abstracts submitted."
    Clinical
    |
    GlycoVision™